Scarica l'app Stockscreener
0.9816
7.40%
-0.0784
Dopo l'orario di chiusura:
1.00
0.0184
+1.87%
Precedente Chiudi:
$1.06
Aprire:
$1
Volume 24 ore:
100.02K
Relative Volume:
0.13
Capitalizzazione di mercato:
$1.46M
Reddito:
-
Utile/perdita netta:
$-7.90M
Rapporto P/E:
-0.00528
EPS:
-185.9263
Flusso di cassa netto:
$-6.29M
1 W Prestazione:
-42.26%
1M Prestazione:
-38.65%
6M Prestazione:
-90.18%
1 anno Prestazione:
-99.76%
Intervallo 1D:
$0.9803
$1.045
Intervallo di 1 settimana:
$0.9199
$1.555
Portata 52W:
$0.9199
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Nome
Clearmind Medicine Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare CMND vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.9816 | 1.57M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
Proposed Nasdaq threshold could threaten Clearmind (NASDAQ: CMND) listing - Stock Titan
Charging Robotics Inc. Sells Majority Stake in Charging Israel to Clearmind Medicine for $2.5M (OTC: CHEV) - Kalkine Media
Clearmind Medicine Announces Yale IRB Approval to Begin Patient Recruitment for CMND-100 Phase I/II Trial in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - The Manila Times
All 24 trial participants completed treatment with no serious adverse events. Yale can now recruit. - Stock Titan
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com South Africa
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - benzinga.com
CMND Stock Slides As Traders Eye Key Support Levels - timothysykes.com
CMND Stock Pops As Clearmind Advances AUD Drug To Phase IIa - timothysykes.com
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
Clearmind Medicine ลงนามในข้อตกลงขั้นสุดท้ายเพื่อเข้าซื้อหุ้น 51% ในบริษัทระบบชาร์จไร้สายสำหรับระบบจอดรถอัตโนมัติและรถแท็กซี่ไร้คนขับ (Robotaxis) - Moomoo
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - The Manila Times
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (CMND) Slips 2.76% to $1.76, Holds Above Key Support at $1.67Hedge Fund Favorites - siam.in
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - The Manila Times
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint - The Manila Times
Clearmind Medicine (CMND) holders report 9.99% cap on warrant-based stake - Stock Titan
Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study - Stock Titan
Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai Formulation - TradingView
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - The Manila Times
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Program - Quiver Quantitative
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, ... - Enidnews.com
Clearmind’s nasal MEAI stays longer on tissue with comparable drug transport - Stock Titan
Clearmind Medicine (CMND) Drops 6.86% to $1.63, Testing Critical Support at $1.55Symmetrical Triangle - vinanet.vn
Clearmind Medicine (CMND) Holds Steady at $1.75 as Traders Eye Resistance Near $1.84Wave Equality - vinanet.vn
Clearmind Medicine (Nasdaq: CMND) wins DSMB nod to advance AUD trial - Stock Titan
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - The Manila Times
CMND-100 Set to Enter Human Testing for Moderate-to-Severe Alcohol Use Disorder - Stock Titan
Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout - Bitget
Clearmind Medicine (CMND) Edges Higher: Biotech Stock Holds Steady Near $1.74 as Support FirmsOvervalued Signals - vinanet.vn
Clearmind Medicine (CMND) Shares Advance Nearly 5% as Biotech Momentum BuildsStop Hunt - dars.gov.et
Clearmind Medicine to acquire 51% stake in EV charging firm By Investing.com - Investing.com Nigeria
Clearmind Medicine Signs Letter Of Intent To Acquire 51% Majority Stake In Ev Wireless Charging Solutions For Automated Parking Systems Company - TradingView
Clearmind Medicine Inc Azioni (CMND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):